Medical Marijuana Appropriations Rider: Federal Protections for State Programs

Executive Summary

The medical marijuana appropriations rider is a one-sentence spending limitation that has barred the Department of Justice from using federal funds to interfere with state medical cannabis programs since December 2014, and it must be renewed in every spending bill. Congress has attached the language, known as the Rohrabacher-Farr amendment and later the Joyce-Blumenauer amendment, to Commerce-Justice-Science (CJS) appropriations measures for more than a decade. It is the most important federal protection available to state-licensed medical operators, patients and caregivers.

On November 13, 2026, The Hype Magazine reported that a Senate appropriations panel proposed extending the state medical marijuana protections without a House-passed provision aimed at blocking the federal rescheduling of marijuana. That report, as summarized in the news feed, is the trigger for this page. The detail that matters: the House and Senate versions of the funding language diverge, and the divergence turns on whether the rider travels alone or with a rider that would restrict the executive branch's ability to move cannabis from Schedule I to Schedule III under the Controlled Substances Act (21 U.S.C. § 801 et seq.).

This hub explains what the rider does and does not do, how it reached its current form, which agencies and lawmakers shape it, how courts have read it, and what operators and patients should watch as the House and Senate reconcile their texts. It is not legal advice, and it does not rely on details beyond what is verifiable in public statutes, court opinions and congressional records. Where the November 2026 negotiations are concerned, treat any figure or text not quoted from a primary source as unconfirmed until the final conference text is released.

Why This Matters

The rider is the thin legal line between a functioning state medical market and federal enforcement exposure, affecting millions of patients and tens of billions of dollars in annual sales. Marijuana remains a Schedule I substance under federal law, meaning every state-licensed cultivator, dispensary and processor operates in violation of 21 U.S.C. § 841 and § 846 in the technical sense. The rider does not change that status. It simply prohibits the Justice Department from spending appropriated dollars to prevent states from implementing their own medical cannabis laws.

Stakeholders

• Patients and caregivers in the roughly 40 states with medical cannabis programs rely on the rider as a practical shield against federal prosecution for compliant conduct.
• Licensed operators, including multi-state operators (MSOs) and single-site dispensaries, use it to defend against federal charges and to reassure lenders, landlords and insurers.
• State regulators in California, Colorado, Ohio, New York and elsewhere depend on it to administer programs without fear of federal interference with their licensing functions.
• Federal prosecutors and the DEA operate within its constraints, as do U.S. Attorneys' offices deciding whether to charge conduct tied to state-licensed businesses.

The scale of exposure

Without the rider, the Justice Department would regain unrestricted budgetary authority to pursue cases against state-compliant medical businesses. The rider has never been permanent law. Because it lives inside annual appropriations bills, it expires with each fiscal year unless Congress renews it, including through continuing resolutions that carry the prior year's language forward. That annual renewal cycle is itself a source of risk: a government shutdown, a failed omnibus or a poison-pill rider can delay or alter the protection.

Why the November 2026 split matters

The House has at times paired medical cannabis protections with language that would prevent the executive branch from using funds to reschedule marijuana. A Senate panel proposing the protections without that anti-rescheduling provision signals a disagreement over whether Congress should constrain the ongoing administrative rescheduling process. For operators, the stakes are twofold: continued protection from enforcement, and the possibility that rescheduling to Schedule III could eliminate the punitive Internal Revenue Code Section 280E tax treatment that currently disallows ordinary business deductions for cannabis sellers.

Background and History

The rider traces to a 2001 first attempt, a 2014 breakthrough, and a decade of renewals that courts have interpreted narrowly but meaningfully.

1996–2001: State programs outrun federal law

California voters approved Proposition 215 in 1996, launching the first modern state medical marijuana program. Federal enforcement continued under the Controlled Substances Act, and in 2001 the Supreme Court held in United States v. Oakland Cannabis Buyers' Cooperative that there is no medical necessity exception to federal marijuana prohibition. In 2005, Gonzales v. Raich confirmed that Congress's Commerce Clause power reaches even locally grown, locally consumed medical marijuana. These rulings left state patients and providers dependent on federal enforcement discretion rather than legal rights.

2001–2013: Early amendment efforts fail

Representative Dana Rohrabacher (R-CA) and Representative Sam Farr (D-CA) first offered a funding-limitation amendment in 2003. It failed on the House floor, as did repeated attempts across the following decade. Support grew incrementally: the 2003 vote drew 152 supporters, and later iterations climbed as public opinion shifted and more states enacted programs. Advocacy groups, including Americans for Safe Access and the Marijuana Policy Project, built the vote-counting and lobbying infrastructure that eventually carried the measure.

2013: The Cole Memo

In August 2013, Deputy Attorney General James Cole issued a Justice Department memorandum setting enforcement priorities, such as preventing distribution to minors and diversion to states where cannabis remained illegal, while signaling that the department would generally defer to state regulatory systems that were robust. The Cole Memo was guidance, not law, and could be rescinded at will, which is precisely why advocates sought statutory protection through appropriations.

2014: The amendment passes

On May 30, 2014, the House approved the Rohrabacher-Farr amendment to the CJS appropriations bill by a vote of 219 to 189, with 49 Republicans joining most Democrats. The language, carried into the Consolidated and Further Continuing Appropriations Act, 2015, was signed into law in December 2014. It barred the Justice Department from using funds to prevent a list of named states and territories from implementing their medical marijuana laws. The text enumerated the jurisdictions then covered, and subsequent years' versions expanded the list as new states adopted programs.

2015–2017: Renewal and the Sessions threat

Congress renewed the rider each year, including through continuing resolutions. After the 2016 election, Attorney General Jeff Sessions wrote to congressional leaders in May 2017 urging them not to renew the protection, arguing it would hamper the department's ability to combat violent crime and drug trafficking. Congress renewed it anyway. In January 2018, Sessions rescinded the Cole Memo and related guidance, leaving the rider as the principal federal protection. By then, Representative Rohrabacher's remaining colleagues, including Representative Earl Blumenauer (D-OR), had taken a leading role, and the provision became known as Rohrabacher-Blumenauer and later Joyce-Blumenauer, reflecting changes in sponsorship.

2016: The Ninth Circuit reads the rider

In United States v. McIntosh (9th Cir. 2016), the Ninth Circuit held that the rider prohibits the Justice Department from spending money on the prosecution of individuals whose conduct is fully compliant with state medical marijuana law. Defendants could seek an evidentiary hearing to show strict compliance, and if they did, the prosecution could not continue to be funded. The court emphasized that substantial compliance was not enough; the standard is strict adherence to state rules. The decision created a pathway for defendants but also a high bar.

2017–2022: Broadening and narrowing

Other federal courts addressed the rider with mixed results. The First Circuit's decision in United States v. Bilodeau (2022) rejected a defendant's reading and held that the rider did not bar prosecution of those whose conduct fell outside strict state-law compliance. The Ninth Circuit's later rulings reinforced the compliance-focused framework. Through these cases, courts established that the rider is a funding restriction, not an immunity; it does not legalize cannabis, create a defense on the merits, or bind a future Congress.

2018–2021: Adult-use markets and the rider's limits

As states legalized adult-use cannabis, advocates noted that the rider's text covers medical programs only. Efforts to extend the language to adult-use markets, including during the 2019 House appropriations cycle, gained attention but never became law in enacted form. Operators in purely adult-use states operate without statutory appropriations protection and rely on enforcement discretion.

2022–2024: Rescheduling enters the picture

In October 2022, President Biden directed a review of marijuana's scheduling. In August 2023, the Department of Health and Human Services recommended moving marijuana to Schedule III. In May 2024, the DEA published a notice of proposed rulemaking (NPRM) to reclassify marijuana, and hearings before an administrative law judge (ALJ) were scheduled and then stalled amid procedural disputes. The rescheduling process became intertwined with appropriations because some House members sought to prohibit funds from being used to carry it out.

2025–2026: The anti-rescheduling rider debate

House appropriators have, in various cycles, advanced language intended to constrain the executive branch's ability to reschedule. The November 2026 reporting that a Senate panel proposed the medical protections without the House's anti-rescheduling provision reflects the latest iteration of this tension: the protective rider is widely supported across party lines, while the anti-rescheduling language is more contested. The final text will be set through bicameral negotiation, and the outcome determines whether the 2027 version of the rider moves alone or carries a restriction on rescheduling activity.

Key Players

A small set of appropriators, advocacy groups and federal agencies decides each year whether the rider survives intact.

House and Senate Appropriations Committees

The CJS subcommittees in each chamber draft the text. The House and Senate versions are reconciled in conference or through an omnibus or minibus package. Because the rider rides on a must-pass spending bill, its fate is tied to the broader appropriations calendar.

Representative Earl Blumenauer and congressional champions

Earl Blumenauer (D-OR) was a longtime co-lead of the amendment, working alongside Republican colleagues such as Dana Rohrabacher (R-CA), and later Representative David Joyce (R-OH), whose name became attached to the amendment. Bipartisan sponsorship has been the rider's survival strategy.

Department of Justice and DEA

The Justice Department is the regulated party, constrained by the rider. The Drug Enforcement Administration, an agency within DOJ, administers the Controlled Substances Act's scheduling process and is the lead on the pending rescheduling rulemaking. The two roles are distinct: the rider limits prosecutorial and enforcement spending, while rescheduling is an administrative reclassification.

FDA and HHS

The Food and Drug Administration conducts the scientific and medical evaluation underlying scheduling recommendations, and the Department of Health and Human Services transmitted the Schedule III recommendation to the DEA. Neither agency is bound by the rider, but their work shapes the rescheduling debate that has become entangled with it.

Advocacy organizations

Americans for Safe Access, the Marijuana Policy Project, the National Cannabis Industry Association and the Drug Policy Alliance have lobbied for renewal each year. On the other side, groups skeptical of cannabis normalization, including Smart Approaches to Marijuana, have opposed expansion and supported constraining executive action on rescheduling.

State regulators and attorneys general

State agencies in places like Colorado, Oregon and Massachusetts rely on the rider for operational stability and have supported renewal. State attorneys general have sometimes weighed in on rescheduling and scheduling-related litigation.

Legal and Regulatory Framework

The rider is a funding limitation layered on top of an unchanged federal prohibition, which means it protects conduct only to the extent courts and prosecutors honor its text.

The statutory baseline

Under 21 U.S.C. § 812, marijuana is listed in Schedule I, defined as having a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision. Manufacture, distribution and possession with intent to distribute are criminalized under 21 U.S.C. § 841, and conspiracy under § 846. The rider does not amend any of these provisions.

What the rider says

The text prohibits the Department of Justice from using appropriated funds to prevent specified jurisdictions from implementing their own laws authorizing the use, distribution, possession or cultivation of medical marijuana. The list of jurisdictions has been updated as states have enacted programs. Because it is a limitation on funds, not a change in substantive law, a future Congress can drop it, and the Justice Department can resume enforcement the day it lapses.

How courts apply it

Under McIntosh, a defendant must show strict compliance with state law to invoke the rider, and the burden is on the defendant at an evidentiary hearing. Courts have generally held that the rider does not provide a defense at trial, does not limit the Bureau of Alcohol, Tobacco, Firearms and Explosives or other non-DOJ agencies, and does not protect conduct that violates state rules. It also does not bar civil actions or asset forfeiture in the same way as criminal prosecution in every circuit; practitioners should check controlling authority.

Federalism overlay

The rider reflects a federalism compromise: Congress leaves the underlying prohibition intact under the Commerce Clause authority affirmed in Gonzales v. Raich, while declining to fund enforcement against state-compliant medical programs. This is distinct from the anti-commandeering doctrine under which states cannot be forced to enforce federal law, a principle reinforced in Murphy v. NCAA (2018).

Rescheduling and its interaction

If marijuana moves to Schedule III, it would still be a controlled substance, and state-licensed businesses would not automatically become federally lawful. Schedule III status would, however, remove marijuana businesses from the reach of Section 280E of the Internal Revenue Code, which denies deductions to traffickers in Schedule I and II substances. It would also change the penalty structure and research environment. The rider and rescheduling operate on separate tracks, but a House provision barring rescheduling funds would directly constrain that track, which is why the Senate panel's decision to omit it matters.

State-by-State Breakdown

The rider covers medical programs in the large majority of states, but its practical value varies with how each state structures its market. The table summarizes representative jurisdictions; operators should confirm current statutory text and program rules before relying on it.

State	Program status	Rider relevance
California	Medical since 1996; adult-use since 2016	Medical operations covered; adult-use outside rider text
Colorado	Medical since 2000; adult-use since 2012	Medical covered; large mixed market
Ohio	Medical program operational; adult-use enacted by ballot in 2023	Medical covered; regulators balance dual markets
New York	Medical since 2014; adult-use since 2021	Medical covered; adult-use rollout ongoing
Florida	Medical program with vertically integrated licensees	Medical covered; adult-use not enacted as of this writing
Texas	Limited low-THC medical program	Narrow program; rider applies to authorized activity

California

California's medical framework predates the rider by nearly two decades, and California operators were central plaintiffs in early federal cases. Most California licensees now hold dual medical and adult-use authority, so the rider covers only part of their activity.

Colorado

Colorado's regulated system serves as a model for enforcement-priority arguments, and its medical sector remains protected under the rider while adult-use sales dominate volume.

Ohio

Ohio's medical program launched later than many peers, and its 2023 adult-use initiative created overlapping regulatory structures. The rider matters for patients and licensed medical operators during the transition.

New York

New York's medical program, dating to 2014, continues alongside a still-maturing adult-use market. Medical licensees rely on the rider while adult-use licensees depend on enforcement discretion.

Texas and other restrictive programs

States with narrow medical programs, such as limited low-THC access, are still within the rider's protective scope for authorized activity, but the practical benefit is limited by the small size of the programs.

Market and Business Implications

The rider underwrites the medical segment's access to capital, banking and insurance, while the rescheduling fight determines whether tax relief under Section 280E is on the horizon.

MSO impact

Multi-state operators have long cited federal legal uncertainty as a driver of discounted valuations and costly financing. The rider offers a modest comfort on enforcement risk but does nothing for banking access, interstate commerce or tax treatment. A clean renewal supports the status quo; a lapse would reintroduce tail risk for medical-focused businesses.

Wholesale pricing read

The rider is unlikely to move wholesale flower prices directly, because it does not change supply, demand or licensing. Price pressure in mature markets such as California and Colorado has been driven by oversupply and compression, not by federal funding limitations. Rescheduling, by contrast, could change operator cash flows through the elimination of 280E exposure, which would indirectly affect pricing power and consolidation incentives.

Capital flows

Investors weigh three federal variables: enforcement risk (the rider), tax treatment (280E and rescheduling) and market access (banking and listing). A split outcome in which the rider is renewed but rescheduling is blocked would preserve the status quo on enforcement while keeping the tax burden in place. A rider paired with unobstructed rescheduling is the most favorable scenario for operator margins.

Operator lens: compliance as legal armor

Because courts require strict compliance under the McIntosh standard, the rider rewards documentation. Operators who maintain seed-to-sale tracking, licensing records and audit trails are better positioned to invoke it. Those who operate in gray areas, such as unlicensed sales or diversion, receive no protection.

What Experts Say

Legal analysts and policy groups agree the rider is valuable but fragile, and they diverge on whether tying it to rescheduling language helps or harms reform.

Advocacy organizations such as the Marijuana Policy Project and Americans for Safe Access have said that annual renewal without conditions is the priority, and that attaching restrictions on rescheduling would undermine the executive branch's ability to align federal law with medical evidence. The groups have consistently urged appropriators to preserve the existing text and extend its logic to adult-use states.

Opponents of rescheduling, including Smart Approaches to Marijuana, have said that Congress should not allow the executive branch to loosen federal controls without legislative approval, and have supported House language limiting funds for the effort. Their position is that the Controlled Substances Act scheduling process requires careful scientific and public-health review.

Legal commentators who track the case law, including practitioners familiar with McIntosh and Bilodeau, have said the rider's practical force depends on judicial reading and on the Justice Department's own charging discretion. They caution that it is not a license and that a defendant bears the burden of showing strict state-law compliance.

The consistent expert view, paraphrased across these camps: the rider is a necessary but insufficient protection, and its value is only as durable as the next appropriations cycle.

What's Next

The decisive moments are the House-Senate reconciliation of CJS text, any continuing resolution deadline, and the status of the DEA's rescheduling rulemaking.

Calendar and decision points

• Committee action: The Senate panel's proposal must be adopted by the full Appropriations Committee and then reconciled with the House's version.
• Fiscal-year deadline: If full-year appropriations are not enacted by the start of the fiscal year, Congress typically passes a continuing resolution that carries forward existing rider language.
• Conference or omnibus negotiation: Differences between House and Senate text, including the anti-rescheduling provision, are resolved here.
• Rescheduling track: The DEA's rulemaking, including any ALJ proceedings and a final rule, continues on a separate timeline subject to litigation and administrative decisions.

Scenarios

1. Clean renewal: The Senate approach prevails; the medical rider is extended without an anti-rescheduling provision. Enforcement protection is preserved and the rescheduling process is unconstrained.
2. Paired outcome: The House provision is adopted alongside the rider. Medical protection continues, but funds for rescheduling activity are restricted, potentially stalling Schedule III reclassification.
3. Short-term extension: A continuing resolution carries the existing rider language forward while negotiations continue, deferring the fight.
4. Lapse or delay: A shutdown or failed package creates a gap, raising legal uncertainty even if brief.

Watch for the final bill text rather than press summaries; the exact wording of any rescheduling limitation determines its practical effect. This hub will be updated with dated sections as the appropriations process advances.

Further Reading

Primary sources provide the authoritative text and case law behind the rider.

• Controlled Substances Act, 21 U.S.C. § 801 et seq.: https://www.law.cornell.edu/uscode/text/21/chapter-13
• Schedules of controlled substances, 21 U.S.C. § 812: https://www.law.cornell.edu/uscode/text/21/812
• Congressional appropriations text and bill tracking: https://www.congress.gov
• House Appropriations Committee: https://appropriations.house.gov
• Senate Appropriations Committee: https://www.appropriations.senate.gov
• United States v. McIntosh, 833 F.3d 1163 (9th Cir. 2016): https://www.courtlistener.com
• Gonzales v. Raich, 545 U.S. 1 (2005): https://www.supremecourt.gov/opinions/slipopinion/04
• DEA Diversion Control Division, scheduling information: https://www.deadiversion.usdoj.gov
• Federal Register, DEA marijuana rescheduling notice of proposed rulemaking: https://www.federalregister.gov
• Internal Revenue Code Section 280E: https://www.law.cornell.edu/uscode/text/26/280E